GlassScriptPhysician profile
Ashraf Hanna
NPI 1619948429
$15,471.61
in general payments reported to CMS, 2019-2025
56 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what 79% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,268 · 2020: $2,058 · 2021: $2,311 · 2022: $2,283 · 2023: $1,834 · 2024: $2,819 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,326 · Travel and Lodging: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,325.73 |
| Travel and Lodging | $225.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,766.10 | 2019-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,307.88 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $1,183.06 | 2019-2025 | Ztlido |
| Boston Scientific Corporation | $1,135.99 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16, General - Pain Management |
| Abbvie INC. | $956.45 | 2021-2025 | |
| Abbott Laboratories | $829.33 | 2019-2025 | Proclaim, Eterna |
| Pfizer INC. | $752.70 | 2019-2025 | |
| Nevro Corp. | $683.06 | 2019-2024 | Senza |
| Protega Pharmaceutials INC | $551.07 | 2022-2025 | Roxybond |
| Supernus Pharmaceuticals, INC. | $474.40 | 2019-2020 | |
| Eisai INC. | $385.05 | 2020-2022 | |
| Allergan, INC. | $369.58 | 2019-2022 | |
| Lilly USA, LLC | $358.09 | 2021-2024 | Reyvow, Emgality |
| Redhill Biopharma INC. | $326.35 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $303.95 | 2020-2021 |
Show all 54 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.